1015 Capital Partners’s Biogen BIIB Stock Holding History

1015 Capital Partners’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.38K	Buy	11 +1	+10%	+$191	﹤0.01%	313
2026 Q1	$1.83K	Hold	10	–	–	﹤0.01%	336
2025 Q4	$1.76K	Buy	+10	New	+$1.63K	﹤0.01%	330

Other funds holding BIIB

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

1015 Capital Partners's BIIB Position: Q2 2026 in Review

1015 Capital Partners increased its Biogen (BIIB) stake by 10% in Q2 2026, buying an estimated $191 and bringing the position to 11 shares worth $2.38K. The position accounts for ﹤0.01% of the portfolio, ranked #313.

1015 Capital Partners first reported a position in BIIB in Q4 2025 and has held it in 3 quarters since. 1,034 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

1015 Capital Partners held 11 shares of Biogen worth $2.38K as of Q2 2026.
1015 Capital Partners bought 1 Biogen share in Q2 2026, an estimated $191.
Biogen made up ﹤0.01% of 1015 Capital Partners's portfolio in Q2 2026, its #313 holding.
1015 Capital Partners first reported a position in Biogen in Q4 2025 and has held it in 3 quarters since.
1,034 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on 1015 Capital Partners's 13F filing for Q2 2026, filed 21 Jul 2026.